1 / 27

Project Summary

mura
Download Presentation

Project Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Project S1Assessment of pharmaceutical residue levels in industrial waste waters and their removal using photocatalysisResearcher: Ann-Marie DeeganPrincipal Investigator’s: Anne Morrissey, Kieran Nolan and John TobinDublin City UniversityCollaborator: Professor Michael Oelgemoeller Industrial Mentor: Clodagh Ettarh, Astellas

  2. Project Summary • Development of techniques for the determination of low levels of pharmaceuticals in industrial wastewater • Development of methods for the removal of pharmaceuticals using photocatalysis • Start date: October 2007 • End date: September 2010

  3. Project Objectives • Develop a SPE-LC-MS/MS detection method for the monitoring of the active pharmaceutical ingredients (APIs) • Monitor pharmaceutical residues in influent and effluent samples • Degrade APIs using photocatalysis

  4. Potential benefits for industry • Techniques for the API determination • Monitoring of APIs in waste streams • Sustainable removal of APIs • Enable compliance with future legislation and terms of licensing • Identify product loss

  5. Routes of entry to the environment

  6. Routes of entry to the environment

  7. Analytes • Active Ingredient A: Famotidine • H2 receptor anatagonist, inhibits stomach acid production • Active ingredient B: Tamsulosin hydrochloride • Blocks alpha receptors, treatment of benign prostatic hyperplasia • Active Ingredient C: Solifenacin succinate • Muscarinic antagonist, used in the treatment of overactive bladder

  8. Detection of APIs in aqueous samples [SPE, SPME, LLE]

  9. Influent Method Limits

  10. Effluent Method Limits

  11. Sampling points

  12. Concentration (mgL-1)

  13. Concentration (mgL-1)

  14. Concentration (mgL-1)

  15. 3rd Nov 2009 - 2nd March 2010 Summary

  16. Removal Techniques • TiO2 photocatalysis • Photo-Fenton oxidation

  17. TiO2 Photocatalysis • generation of electron-hole pairs h+-e– • formation of highly reactive HO• radicals

  18. Immersion Well Experiment Active Ingredient A Figure: Degradation of active ingredient A and degradation products monitored over 300 min

  19. Immersion Well Experiment Active Ingredient A Figure: Degradation of active ingredient A and degradation products monitored over 300 min Figure: Initial monitoring of degradation products using HPLC identification of breakdown products will be conducted using mass spectrometry

  20. Enviolet Reactor Experiment UV Degradation of active ingredient A monitored from 190 nm to 350 nm over 300 min

  21. Enviolet Reactor Experiment UV Degradation of active ingredient A monitored from 190 nm to 350 nm over 300 min Degradation of active ingredient A and degradation products monitored over 300 min

  22. Dark Fenton OH· OH· Photo-Fenton oxidation Photo-Fenton at pH 3 H2O Fe3+ H2O2 Fe2+

  23. Dark Fenton OH· OH· Photo-Fenton oxidation Photo-Fenton at pH 3 H2O Fe3+ H2O2 Fe2+

  24. Dark Fenton OH· OH· Photo-Fenton oxidation Photo-Fenton at pH 3 H2O Fe3+ H2O2 Fe2+

  25. Summary and future work • SPE-LC-MS/MS method developed and validated • 6 month sampling programme complete • TiO2 photocatalysis and Fentons oxidation both show high removal efficiency • Continuation of Fenton experiments

  26. Any Questions?

More Related